This randomized phase II study will assess the impact of pre-conditioning on migration and
survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive
resection and completed standard temozolomide (TMZ) and radiation treatment, as well as the
impact of tetanus pre-conditioning and basiliximab together on survival. After completing
standard of care radiotherapy with concurrent TMZ, patients will be randomized to 1 of 3
treatment arms: 1). receive cytomegalovirus (CMV)-specific dendritic cell (DC) vaccines with
unpulsed (not loaded) DC pre-coinditioning prior to the 4th vaccine; 2). receive CMV-specific
DC vaccines with Tetanus-Diphtheria Toxoid (Td) pre-conditioning prior to the 4th vaccine;
3). receive basiliximab infusions prior to the 1st and 2nd DC vaccines along with Td
pre-conditioning prior to the 4th vaccine. A permuted block randomization algorithm using a
1:1:1 allocation ratio will be used to assign patients to a treatment arm. Randomization will
be stratified by CMV status (positive, negative), with the assignment to arms I and II being
double-blinded. Effective March 2017, randomization to Group III has been terminated.